Avita Medical

Avita Medical Limited is a publicly listed, global medical technology company trading on the Australian Stock Exchange (ASX:AVH) and OTC Markets (OTCQX:AVMXY).

Avita Medical Ltd specialises in innovative medical therapeutic devices for two categories;
 - Regenerative Medicine.
 - Respiratory Products.

The company is predominately well know and is gaining large market momentum for its innovative regenerative medicine: ReCell.
ReCell is a spray on skin using patients own cells for regenerative healing of burns, ulcers, wounds and cosmetic procedures. ReCell is a kit that enables the spray application to be delivered in 30 minutes onsite, eliminating laboratory studies for medical diagnosis and treatment.

Respiratory Products
Breath-A-Tech. Created in Australia, it is the market leader in the delivery of respiratory medicine to asthma sufferers. The products technology is highlighted for its effectiveness of delivering medicine. Along with its effectiveness, it is easy to use, compact, and can withstand hospital grade cleaning, autoclaving; a device used to disinfects medical equipment with high pressure steam at 121 degrees. 

Funhaler. Designed to effectively deliver medicine to children suffering asthma.  Its design encompasses a wheel spin and whistle to capture the child's attention. This provides positive reinforcement and a 'play time' association for children whilst delivering successful dosages of respiratory medicine.  

Avita Medical major growth is in its innovative regenerative medicine: ReCell.
ReCell was introduced into the market in 2008 under its former company name clinical cell culture. It since has been restructured under its new company name Avita Medical by its new CEO; William Dolphin.

Avita Medical operations currently see the company collaborating with surgeons all over the world on clinical trails for different ailments and wounds. Avita Medical has been growing the product by  these trials, gaining support from surgeons, creating subsidiary's and setting up patents internationally to ensure exclusive commercial rights. Currently studies are underway in China, UK, Italy and Germany.

ReCell is currently approved for marketing and sales in Europe, Canada and Australia, but not approved for marketing in the USA.

In 2013 Avita Medical received a $880k grant from the US Department of Defence for US FDA clinical trials in the treatment of burns for regulatory clearance in the USA for marketing and sales.

Avita Medical is continuing to make steady growth with ReCell as a key product in regenerative medicine. Early adopters of Avita's ReCell Technology forms it core audience and has seen steady growth which provides positive insight for its future sales. Total revenue for year ending 2013 was $4.1 million. In 2011 revenue rose by 59% and in 2012 ReCell had a growth by 85%.

Over the next 12-18 months the company will be focusing on its clinical trail programs and improvements to ReCell and regenerative technology to see a steady impact to shareholders and increase recognition and usage from surgeons worldwide.

http://www.avitamedical.com/index.php